ВАК (Россия)
РИНЦ (Россия)
EBSCO
Регистрационное агентство DOI (США)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

ЛЕКАРСТВЕННЫЕ СРЕДСТВА ПРИ РАССЕЯННОМ СКЛЕРОЗЕ: НАСТОЯЩЕЕ И БУДУЩЕЕ

Скачать статью в PDF
Номер журнала: 
9
Год издания: 
2015

А. Волков (1), кандидат медицинских наук, И. Крылова (2), профессор, доктор медицинских наук 1 -Городская поликлиника №69, Москва 2 -Первый МГМУ им. И.М. Сеченова E-mail: krylirina@gmail.com

Рассматриваются основные препараты для лечения рассеянного склероза и механизмы их действия.

Ключевые слова: 
рассеянный склероз
препараты
изменяющие течение рассеянного склероза

Для цитирования
Волков А., Крылова И. ЛЕКАРСТВЕННЫЕ СРЕДСТВА ПРИ РАССЕЯННОМ СКЛЕРОЗЕ: НАСТОЯЩЕЕ И БУДУЩЕЕ . Врач, 2015; (9): 15-21


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Aktas O., Kury P., Kieseier B., Hartung H.P. Fingolimod is a potential novel therapy for multiple sclerosis // Nat. Rev. Neurol. – 2010; 6: 373–82.
  2. Bielekova B., Howard T., Packer A. et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis // Arch. Neurol. – 2009; 66: 483–9.
  3. Bielekova B., Becker B. Monoclonal antibodies in MS: mechanisms of action // Neurology. – 2010; 74: 31–40.
  4. Berger J. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies // Am. J. Manag. Care. – 2011; 17 (Suppl. 5): 146–53.
  5. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system // Br. J. Pharmacol. – 2009; 158: 1173–82.
  6. Cadavid D., Wolansky L., Skurnick J. et al. Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study // Neurology. – 2009; 72 (23): 1976–83.
  7. Calabresi P., Goodin D., Jeffery D. et al. Efficacy and Safety of Fingolimod Versus Placebo: Primary Outcomes from the Phase 3 FREEDOMS II Study in Patients with Relapsing-Remitting Multiple Sclerosis / Lyon, France: ECTRIMS, 2012.
  8. Calabresi P., Kieseier B., Arnold D. et al. Clinical Efficacy and Safety of Peginterferon Beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study / San Diego, USA: AAN, 2013.
  9. Comi G., Jeffery D., Kappos L. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis // N. Engl. J. Med. – 2012; 366: 1000–9.
  10. Deogracias R., Yazdani M., Dekkers M. et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome // Proc. Natl. Acad. Sci. USA. – 2012; 109: 14230–5.
  11. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurogeneration in MS // Exp. Neurol. Epub. – 2014; 262 (Pt. A): 8–17.
  12. Ford C., Johnson K., Lisak R. et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients // Mult. Scler. – 2006; 12 (3): 309–20.
  13. Gold R., Giovannoni G., Selmaj K. et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial // Lancet. – 2013; 381: 2167–75.
  14. Gorelik L., Lerner M., Bixler S. et al. Anti-JC virus antibodies: implications for PML Risk Stratification // Ann. Neurol. – 2010; 68: 295–303.
  15. Hu Y., Turner M., Shields J. et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model // Immunology. – 2009; 128: 260– 70.
  16. Irvine K., Blakemore W. Remyelination protects axons from demyelination-associated axon degeneration // Brain. – 2008; 131: 1464–77.
  17. Kappos L., Radue E., O’Connor P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis // N. Engl. J. Med. – 2010; 362: 387–401.
  18. Kappos L., Li D., Calabresi P. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial // Lancet. – 2011; 378: 1779–87.
  19. Kim S., Kim W., Li X. et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? // Mult. Scler. – 2012; 18 (10): 1480–3.
  20. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis // Lancet Neurol. – 2008; 7: 626–36.
  21. Martinelli V., Cocco E., Capra R. et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone // Neurology. – 2011; 77: 1887–95.
  22. Meissner M., Valesky E., Kippenberger S. et al. Dimethyl fumarate – only an anti-psoriatic medication? // J. Dtsch. Dermatol. Ges. – 2012; 10: 793–801.
  23. Metz L., Sabuda D., Hilsden R. et al. Gastric tolerance of high-dose pulse in multiple sclerosis // Neurology. – 1999; 53: 2093–6.
  24. Mi S., Miller R., Lee X. et al. LINGO-1 negatively regulates myelination by oligodendrocytes // Nat. Neurosci. – 2005; 8: 745–51.
  25. Mikol D., Barkhof F., Chang P. et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study): a multicentre, randomised, parallel, open-label trial // Lancet Neurol. – 2008; 7 (10): 903–14.
  26. Nickerson M., Marrie R. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry // BMC Neurol. – 2013; 13: 119.
  27. Noseworthy J., Lucchinetti C., Rodriguez M. et al. Multiple sclerosis // N. Engl. J. Med. – 2000; 343 (13): 938–52.
  28. Noseworthy J., Wolinsky J., Lublin F. et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results North American Linomide Investigators // Neurology. – 2000; 54: 1726–33.
  29. Nylander A., Hafler D. Multiple sclerosis // J. Clin. Invest. – 2012; 122 (4): 1180–8.
  30. O’Connor P., Goodman A., Kappos L. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis // Neurology. – 2011; 76: 1858–65.
  31. O’Connor P., Wolinsky J., Confavreux C. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis // N. Engl. J. Med. – 2011; 365: 1293–303.
  32. O’Connor P., Wolinsky J., Confavreux C. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis // N. Engl. J. Med. – 2012; 365: 1293–303.
  33. Ontaneda D., Rae-Grant A. Management of acute exacerbations in multiple sclerosis //Ann. Indian Acad. Neurol. – 2009; 12: 264–72.
  34. Polman C., Reingold S., Banwell B. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria // Ann. Neurol. – 2011; 69 (2): 292–302.
  35. Rae-Grant A., Eckert N., Bartz S. et al. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity // Mult. Scler. – 1999; 5: 179–83.
  36. Ross A., Ben-Zacharia A., Harris C. et al. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone // Front. Neurol. – 2013; 4 (21): 1–12.
  37. Saccardi R., Mancardi G., Solari A. et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life // Blood. – 2005; 105: 2601–7.
  38. Saidha S., Eckstein C., Calabresi P. New and emerging disease modifying therapies for multiple sclerosis // Ann. NY Acad. Sci. – 2012; 1247: 117–37.
  39. Schwid S., Panitch H. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis // Clin. Ther. – 2007; 29 (9): 2031–48.
  40. Scott L. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis // CNS Drugs. – 2013; 27 (11): 971–88.
  41. Sellebjerg F., Barnes D., Filippini G. et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses // Eur. J. Neurol. – 2005; 12: 939–46.
  42. Sellebjerg F., Frederiksen J., Nielsen P. et al. Double-blind, randomized, placebocontrolled study of oral, high-dose methylprednisolone in attacks of MS // Neurology. – 1998; 51: 529–34.
  43. Sladkova V., Mares J., Lubenova B. et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy // Neurol. Endocrinol. Lett. – 2011; 32 (1): 4–6.
  44. Thone J., Ellrichmann G., Seubert S. et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor // Am. J. Pathol. – 2012; 180: 267–74.
  45. Wee Yong V., Chabot S., Stuve O. et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action // Neurology. – 1998; 51: 682–9.